Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Articles|July 23, 2004

FDA creates new oncology office and program

The FDA has consolidated three existing areas within the Center for Drug Evaluation and Research to form the Office of Oncology Drug Products.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer

ByHannah Clarke

June 8th 2026

Study suggests potential diuretic effect with nadofaragene firadenovec

ByAbigail Keller, MD

June 8th 2026

Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026

ByClint D. Bahler, MD

June 5th 2026

The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD

ByAdam B. Weiner, MD,Chad Tang, MD

June 5th 2026

RAD-IO: Durvalumab plus chemoradiotherapy is feasible in MIBC

ByBenjamin P. Saylor, Strategic Content Lead

June 5th 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Trending on Urology Times

The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD

Study suggests potential diuretic effect with nadofaragene firadenovec

Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC

Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026

Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer